Carol Beadling

<i>KIT</i> Gene Mutations and Copy Number in Melanoma Subtypes

Carol Beadling, Erick Jacobson‐Dunlop, F. Stephen Hodi et al. · Clinical Cancer Research · 2008 · 636 citations · Full text

Medicine, Genetics, Oncology +17

Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

F. Stephen Hodi, Christopher L. Corless, Anita Giobbie‐Hurder et al. · Journal of Clinical Oncology · 2013 · 595 citations · Full text

Medicine, Dermatology, Oncology +17

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

Ariel López-Chávez, Anish Thomas, Arun Rajan et al. · Journal of Clinical Oncology · 2015 · 235 citations

Medicine, Molecular Medicine, Oncology +17

Activation of JAK kinases and STAT proteins by interleukin‐2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes.

Carol Beadling, Dmitry Guschin, Bruce A. Witthuhn et al. · The EMBO Journal · 1994 · 213 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Interleukin‐2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway.

Carol Beadling, J. Ng, J. W. Babbage et al. · The EMBO Journal · 1996 · 169 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15